Form 4: Ensign Group VP Beverly Wittekind Reports Stock Option Exercise and Sale
SEC Form 4
Beverly Wittekind, VP and Chief Legal Officer of Ensign Group, exercised stock options and sold shares on May 16, 2025, according to a Form 4 filing.
Summary
- Beverly Wittekind, VP and Chief Legal Officer of Ensign Group, filed a Form 4 detailing changes in beneficial ownership.
- On May 15, 2025, Wittekind acquired 1,000 shares of common stock.
- On May 16, 2025, Wittekind exercised options to acquire 3,539 shares at $15.80 per share.
- Also on May 16, 2025, Wittekind sold 3,539 shares at $150 per share.
- Following these transactions, Wittekind directly owns 39,209 shares of common stock.
- Wittekind also holds options to purchase 2,500 shares of common stock at an exercise price of $147.04.
- The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 12, 2024.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard regulatory filing detailing stock transactions. The sale at $150 could be seen as slightly positive, but it's part of a pre-planned trading strategy.
Positives
- The sale of shares at $150 indicates a potentially positive market valuation at the time of the transaction.
Future Outlook
The document does not contain specific forward-looking statements regarding the company's future performance, but it does detail future vesting dates for stock options.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It provides transparency into the trading activities of company insiders.
Comparison to Industry Standards
- Executive compensation packages including stock options are standard practice in publicly traded companies like Ensign Group.
- Rule 10b5-1 trading plans are frequently used by executives to avoid accusations of insider trading, similar to practices at companies like HCA Healthcare and Brookdale Senior Living.
- The vesting schedules and exercise prices are typical for executive stock option grants, aligning with industry norms observed in companies such as LifePoint Health.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but the overall effect is likely minimal.
Key Dates
| Date | Description |
|---|---|
| 09/12/2024 | Date of adoption of Rule 10b5-1 trading plan |
| 05/15/2025 | Acquisition of 1,000 shares of common stock and grant of employee stock options |
| 05/16/2025 | Exercise of stock options and sale of shares |
| 05/19/2025 | Date of Form 4 signature |
| 05/15/2026 | First vesting date for new stock options |
| 05/25/2027 | Expiration date for previously granted options |
| 05/15/2035 | Expiration date for new stock options |
Keywords
Form 4, Beneficial Ownership, Stock Options, ENSG, Ensign Group, Wittekind, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.